JP4948728B2 - 癌診断用抗体 - Google Patents

癌診断用抗体 Download PDF

Info

Publication number
JP4948728B2
JP4948728B2 JP2001516927A JP2001516927A JP4948728B2 JP 4948728 B2 JP4948728 B2 JP 4948728B2 JP 2001516927 A JP2001516927 A JP 2001516927A JP 2001516927 A JP2001516927 A JP 2001516927A JP 4948728 B2 JP4948728 B2 JP 4948728B2
Authority
JP
Japan
Prior art keywords
epha2
cells
reagent
metastatic
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001516927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507023A5 (enExample
JP2003507023A (ja
Inventor
スコット キンチ，マイケル
ドッジ ザンテク，ニコル
イー． キルパトリック，キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2003507023A publication Critical patent/JP2003507023A/ja
Publication of JP2003507023A5 publication Critical patent/JP2003507023A5/ja
Application granted granted Critical
Publication of JP4948728B2 publication Critical patent/JP4948728B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2001516927A 1999-08-17 2000-08-17 癌診断用抗体 Expired - Fee Related JP4948728B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
US60/149,259 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007211843A Division JP2007291140A (ja) 1999-08-17 2007-08-15 癌診断用抗体
JP2011287158A Division JP2012103264A (ja) 1999-08-17 2011-12-28 癌診断用抗体

Publications (3)

Publication Number Publication Date
JP2003507023A JP2003507023A (ja) 2003-02-25
JP2003507023A5 JP2003507023A5 (enExample) 2008-06-05
JP4948728B2 true JP4948728B2 (ja) 2012-06-06

Family

ID=22529464

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001516927A Expired - Fee Related JP4948728B2 (ja) 1999-08-17 2000-08-17 癌診断用抗体
JP2007211843A Pending JP2007291140A (ja) 1999-08-17 2007-08-15 癌診断用抗体
JP2011287158A Pending JP2012103264A (ja) 1999-08-17 2011-12-28 癌診断用抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007211843A Pending JP2007291140A (ja) 1999-08-17 2007-08-15 癌診断用抗体
JP2011287158A Pending JP2012103264A (ja) 1999-08-17 2011-12-28 癌診断用抗体

Country Status (8)

Country Link
EP (2) EP2312316A1 (enExample)
JP (3) JP4948728B2 (enExample)
AT (1) ATE483978T1 (enExample)
AU (1) AU785445C (enExample)
CA (1) CA2382655A1 (enExample)
DE (1) DE60045075D1 (enExample)
ES (1) ES2357296T3 (enExample)
WO (1) WO2001012840A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1453530A2 (en) * 2001-11-09 2004-09-08 Neuronova AB Method of proliferation in neurogenic regions
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
CA2542631A1 (en) * 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
ATE483978T1 (de) 2010-10-15
EP2312316A1 (en) 2011-04-20
EP1210603A2 (en) 2002-06-05
JP2007291140A (ja) 2007-11-08
AU785445C (en) 2008-01-31
ES2357296T3 (es) 2011-04-25
WO2001012840B1 (en) 2001-09-27
AU785445B2 (en) 2007-06-14
AU6784300A (en) 2001-03-13
JP2003507023A (ja) 2003-02-25
DE60045075D1 (de) 2010-11-18
WO2001012840A3 (en) 2001-05-03
CA2382655A1 (en) 2001-02-22
JP2012103264A (ja) 2012-05-31
EP1210603B1 (en) 2010-10-06
WO2001012840A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
JP4948728B2 (ja) 癌診断用抗体
US20070161064A1 (en) Antibodies as a cancer diagnostic
EP1996940B1 (en) Detection of cancer by elevated levels of bcl-2
Uchino et al. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung
JP5384672B2 (ja) 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
CN112345755A (zh) 乳腺癌的生物标志物及其应用
Sugano et al. Combined measurement of the c‐erbb‐2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse
JP5265140B2 (ja) 卵巣癌の検出方法及び検出用キット
WO2008028066A2 (en) Boris isoforms and methods of detecting and treating disease
JP2012531606A (ja) Δ１３３ｐ５３βを用いた転移癌を有する素因があると思われる被験体の検査方法
KR20090029868A (ko) 체액 내 간암 마커로서의 아넥신 2 및 이를 이용한 간암진단 키트
CN101389962A (zh) 用于诊断胃癌的作为标记的mac-2bp
WO2005005957A2 (en) Method of detecting cancer using delta-catenin
WO2006101847A2 (en) Methods and kit for detecting breast cancer
US20130203059A1 (en) Method for Diagnosis of Bladder Cancer and Related Kits
US20130095483A1 (en) Predictive biomarkers for breast cancer
Class et al. Patent application title: Method for Diagnosis of Bladder Cancer and Related Kits Inventors: Antonio Feliciello (Parete, IT) Luigi Insabato (Napoli, IT) Assignees: Topogen, Inc.
AU2011253563A1 (en) Anti-epha2 antibodies as a cancer diagnostic
CN119162323A (zh) Lrtor在nsclc奥希替尼耐药及转移的预警、指引奥希替尼临床用药及疾病预后中的应用
US8313917B2 (en) Methods of diagnosing latent and active malignancies
AU2007202091A1 (en) Anti-epha2 antibodies as a cancer diagnostic

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20040524

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110421

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120214

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120307

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150316

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees